These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28825763)

  • 1. Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitors.
    Conigliaro P; Triggianese P; Chimenti MS; Tonelli M; Sunzini F; Kroegler B; Perricone R
    Isr Med Assoc J; 2017 Aug; 19(8):467-472. PubMed ID: 28825763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.
    Hamann PDH; Pauling JD; McHugh N; Shaddick G; Hyrich K;
    Rheumatology (Oxford); 2019 Dec; 58(12):2162-2169. PubMed ID: 31155669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.
    Pomirleanu C; Ancuta C; Miu S; Chirieac R
    Clin Rheumatol; 2013 May; 32(5):665-70. PubMed ID: 23292520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients.
    Kojima T; Takahashi N; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Shioura T; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Terabe K; Takemoto T; Asai N; Ishiguro N
    Clin Rheumatol; 2016 Jan; 35(1):219-25. PubMed ID: 26631102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.
    Gamboa-Cárdenas RV; Ugarte-Gil MF; Loreto M; Sacnun MP; Saurit V; Cardiel MH; Soriano ER; Pisoni C; Galarza-Maldonado CM; Rios C; Radominski SC; Castelar-Pinheiro GDR; Bianchi WA; Appenzeller S; da Silveira IG; de Freitas Zerbini CA; Caballero-Uribe CV; Rojas-Villarraga A; Guibert-Toledano M; Ballesteros F; Montufar R; Vázquez-Mellado J; Esquivel-Valerio J; De La Torre IG; Barile-Fabris LA; Palezuelos FI; Andrade-Ortega L; Monge P; Teijeiro R; Achurra-Castillo ÁF; Esteva Spinetti MH; Alarcón GS; Pons-Estel BA
    Clin Rheumatol; 2019 Oct; 38(10):2737-2746. PubMed ID: 31161486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
    Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M
    Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
    Ganhão S; Lucas R; Fonseca JE; Santos MJ; Gonçalves DR; Madeira N; Silva C; Dourado E; Freitas R; Rodrigues J; Azevedo S; Rocha TM; Ferreira RM; Garcia S; Fernandes BM; Prata AR; Couto M; Torres RP; Cunha I; Costa L; Bernardes M
    Acta Reumatol Port; 2020; 45(4):245-252. PubMed ID: 33420771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
    Vastesaeger N; Kutzbach AG; Amital H; Pavelka K; Lazaro MA; Moots RJ; Wollenhaupt J; Zerbini CA; Louw I; Combe B; Beaulieu A; Schulze-Koops H; Dasgupta B; Fu B; Huyck S; Weng HH; Govoni M; Durez P
    Rheumatology (Oxford); 2016 Aug; 55(8):1466-76. PubMed ID: 27114562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
    Aramaki T; Kawakami A; Iwamoto N; Fujikawa K; Kawashiri SY; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Furuyama M; Matsuoka N; Ueki Y; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(6):652-6. PubMed ID: 19787419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
    Yoshioka Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Kanda H; Takagi H; Ito T; Kato T; Saito K; Funahashi K; Asai S; Takemoto T; Terabe K; Asai N; Ishiguro N; Kojima T
    Mod Rheumatol; 2016; 26(2):169-74. PubMed ID: 26140467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts.
    Baganz L; Richter A; Albrecht K; Schneider M; Burmester GR; Zink A; Strangfeld A
    Semin Arthritis Rheum; 2019 Jun; 48(6):976-982. PubMed ID: 30316460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries.
    Keystone EC; Rampakakis E; Movahedi M; Cesta A; Stutz M; Sampalis JS; Nantel F; Maslova K; Bombardier C
    J Rheumatol; 2020 Apr; 47(4):510-517. PubMed ID: 31263067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.